Unused Forest Labs facility snapped up by Aprecia Pharmaceuticals

A Blue Ash, OH, facility to be occupied by Aprecia

A startup aiming to use 3-D printing to make quick-dispersing pharmaceuticals will occupy an Ohio plant left vacant by Forest Laboratories after its buyout by Actavis ($ACT).

Pennsylvania-based Aprecia Pharmaceuticals this week announced its intention to lease the never-used facility in Blue Ash, OH, built by Forest in 2013. The 190,000-square-foot facility cost Forest nearly $45 million, but was deemed redundant after the Actavis acquisition. Cincinnati United Contractors then purchased it as an investment for $14 million, reports the Cincinatti Business Courier.

Aprecia will lease the facility from CUC and will invest $25 million there, creating approximately 150 jobs.

Though not approved, Aprecia has been developing its ZipDose drug delivery system for a decade, and says it provides for the rapid dispersion of therapeutic products through "fast melt" dosage. The company submitted its first New Drug Application to the FDA in October 2014, and it says marketing approval is anticipated during the second half of this year.

"Having evaluated a number of options for reaching our long-term commercial manufacturing goals, Aprecia believes that the state of the art facility in Blue Ash, Ohio, is particularly well suited to showcase our proprietary 3DP technology platform," said Aprecia CEO Don Wetherhold. "The facility has ample space to accommodate our proprietary manufacturing machines and equipment assemblies in the capacity necessary to achieve our projected commercial production volumes well into the future."

- here's the release
- get more from the Cincinatti Business Courier

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.